{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000036","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.487031+00:00","generated_at":"2026-06-02T16:12:57.657595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M","bullets":["Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.","GAAP diluted EPS $0.60; non-GAAP diluted EPS $0.79, vs $0.29 and $0.47 in Q1 2023.","Adjusted EBITDA $115.7M, up 56% from $74.3M; cash and securities $463.5M at quarter end.","Reiterated FY 2024 guidance: revenue $915-985M, adjusted EBITDA $535-585M, non-GAAP EPS $3.55-$3.90.","New $750M share repurchase program announced; partner milestones include $15M from BMS for nivolumab SC."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000036","json":"https://secwatch.observer/filing/0001159036-24-000036.json","markdown":"https://secwatch.observer/filing/0001159036-24-000036.md","text":"https://secwatch.observer/filing/0001159036-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/halo-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:12:57.657595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"303f2d0710754b66904b6138dfe4fcec03e9bef6","claim":"HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $195.9 million, net income $76.8 million. Guidance reaffirmed.","evidence_excerpt":"any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$195.9 million"},{"label":"Net income","value":"$76.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}